M. Mannhart-Harms

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

R. Herrmann, K. Zaman, R. Winterhalder, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

5019 Pegylated liposomal doxorubicin and Bevacizumab as first-line therapy for locallyrecurrent or metastatic breast cancer – a multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)

K. Zaman, R. Winterhalder, C. Rochlitz, 2009 .